Clinical Trials on Carcinoma, Small Cell

Total 44419 results

Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Small Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
Peregrine Pharmaceuticals

Completed

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | Non-Small-Cell Lung Cancer Stage IIIB | Non-Small-Cell Lung Cancer Stage IV | Non-Small-Cell Lung Cancer Metastatic

United States, Australia, Belgium, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Taiwan, Ukraine
Mayo Clinic

Recruiting

Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Malignant Solid Neoplasm | Melanoma | Renal Cell Carcinoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Lung Small Cell Carcinoma

United States
Tufts Medical Center
Partner Therapeutics, Inc.

Recruiting

A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Advanced Lung Non-Small Cell Carcinoma | Non-Small Cell Carcinoma of Lung, TNM Stage 4

United States
Maximilian Diehn
Varian Medical Systems

Completed

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Duke University

Completed

Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer (TOP 1502)

Non-small Cell Lung Carcinoma

United States
Transgene

Terminated

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME)

Non-Small-Cell Lung Carcinoma

United States, France, Hungary, United Kingdom, Spain, Israel, Belgium, Germany, Poland, Italy
Novartis Pharmaceuticals

Completed

Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Carcinoma

United States
University of Cologne

Completed

Molecular Imaging With Erlotinib and Bevacizumab (MIMEB)

Non-Small-Cell Lung Carcinoma

Germany
Sanofi

Terminated

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Non-Small-Cell Lung Carcinoma

France
Maastricht Radiation Oncology
Pfizer

Completed

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

Non Small Cell Lung Carcinoma

Netherlands
Maastricht Radiation Oncology

Completed

HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy

Non-Small-Cell Lung Carcinoma

Netherlands
Aktion Bronchialkarzinom e.V.

Completed

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Non-Small-Cell Lung Carcinoma

Germany
Telik

Completed

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States, Australia, Brazil, Chile, Germany, Argentina, Italy, United Kingdom
Eli Lilly and Company

Completed

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

United States
Eli Lilly and Company

Completed

Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

Argentina, Brazil, Chile, Mexico
University of Washington
National Cancer Institute (NCI)

Completed

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
Hasselt University
Jessa Hospital; University Hospital, Ghent; University Ghent

Recruiting

Investigating the Feasibility of a Physical Activity (Tele)Coaching Intervention in Patients With Non-small Cell Lung Cancer: an Explorative Study (LUCA-coach)

Non-small Cell Lung Cancer | Non-small Cell Carcinoma

Belgium
Intergroupe Francophone de Cancerologie Thoracique
Centre Hospitalier Universitaire de Besancon

Completed

Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up

Non-Small-Cell Lung Carcinoma

France
Kanazawa University

Unknown

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer (VICTORY-J)

Non-Small-Cell Lung Carcinoma

Japan
Lyudmila Bazhenova, M.D.
AstraZeneca

Terminated

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States
University of Paris 5 - Rene Descartes

Completed

Hypermetabolism in the Elderly Lung Cancer Patient (HELP)

Non-small Cell Lung Carcinoma

France
Eli Lilly and Company

Completed

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
Instituto Nacional de Cancer, Brazil
Eli Lilly and Company

Completed

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 (PS2)

Non Small Cell Lung Carcinoma

Brazil, United States
AstraZeneca

Withdrawn

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (IMAC/Herbst)

Non-Small-Cell Lung Carcinoma
AstraZeneca

Completed

SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients (SELINE)

Non Small Cell Lung Carcinoma

Korea, Republic of
Eisai Inc.

Completed

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Non-Small-Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States
Addario Lung Cancer Medical Institute

Terminated

Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network (CASTLE)

Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Metastatic
Cancer Research and Biostatistics Clinical Trials...
Washington University School of Medicine; Lucille P. Markey Cancer Center at...

Completed

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Small Cell Lung Carcinoma | Non Small Cell Lung Carcinoma | Irinotecan Sensitive Cancers

United States
Stanford University

Terminated

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Lung Cancer | Mesothelioma | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC)

United States
Samsung Medical Center

Not yet recruiting

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | EGFR T790M

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States
European Organisation for Research and Treatment...

Unknown

Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo (EVIDENCE)

Non-small Cell Lung Carcinoma

Italy, United Kingdom
Trans Tasman Radiation Oncology Group
Cancer Council Queensland; Victorian Cancer Council

Completed

Chemoradiotherapy in Patients With Localised Lung Cancer

Non Small Cell Lung Carcinoma

Australia
Agenus Inc.

Completed

Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

Lung Cancer | Non-Small-Cell Lung Carcinoma | Pulmonary Cancer

United Kingdom
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
Roswell Park Cancer Institute

Completed

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Gene Mutation

United States
Fox Chase Cancer Center
National Comprehensive Cancer Network

Recruiting

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Non-Small Cell Carcinoma of Lung, TNM Stage 4

United States
Guangdong Association of Clinical Trials

Recruiting

A Real World Study Based on NGS (TRUMPRWS) (TRUMPRWS)

Non-Small Cell Carcinoma of Lung, TNM Stage 4

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...

United States
Groupe Français de Pneumo-Cancérologie

Completed

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) (EGFR-RETRO)

NSCLC Non Small Cells Lung Cancer

France
Boehringer Ingelheim

Recruiting

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

Small Cell Lung Carcinoma (SCLC)

United Kingdom, Germany, France, Poland
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
University Health Network, Toronto

Recruiting

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Non-small Cell Carcinoma

Canada
Washington University School of Medicine
BioMarin Pharmaceutical

Withdrawn

Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Solid Tumors | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
University of California, Davis
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

KRAS Gene Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Recurrent Non-Squamous Non-Small Cell Lung Carcinoma | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States

Clinical Trials on Carcinoma, Small Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations